Day: September 29, 2025

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of the specific modality of radiation therapy usedNEEDHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, presented subgroup analyses focused on the radiation regimen from the Company’s positive phase 3 clinical trial of CAN-2409 (aglatimagene besadenovec) in patients with intermediate-to-high-risk localized prostate cancer at the 2025 Annual Meeting of the American Society for Radiation...

Netanya, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today announced that it has received a new purchase order valued at approximately $100,000 from a leading military unit for its tactical headset systems and related communication accessories. This order marks another milestone in Silynxcom’s ongoing commitment to equipping elite military forces with advanced communication solutions. The Company’s tactical headsets, renowned for their combat-proven reliability, provide superior situational awareness, active hearing protection, and seamless integration with professional-grade ruggedized radios. These features ensure clear and precise communication in high-intensity operational environments,...

KETAFREE™ to provide innovative, preservative-free IV ketamine formulation, eliminating toxic preservatives, in keeping with current HHS priorities to eliminate toxic preservatives from foods and drugs Filing is based on FDA interaction and approval of Suitability Petition for NRx’s proposed strength of preservative-free ketamine This presentation of ketamine represents a reshoring of a strategically important drug to the US, in keeping with the Presidential Executive Order signed on May 5, 2025. Ketamine faces a current US drug shortage not expected to abate in the near future1 Current ketamine market estimated at $750 million and projected to reach $3.35 billion globally in 2034.2 NRx anticipates marketing KETAFREE™ for currently approved ketamine indications The Company has filed a citizen’s petition with the FDA to remove...

VANCOUVER, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) — Asante Gold Corporation (TSXV:ASE | GSE:ASG OTCQX:ASGOF) (“Asante” or the “Company”), an emerging mid-tier gold producer, is pleased to provide an update on progress made on its sulphide plant at the Bibiani Gold Mine (“Bibiani Mine” and “Bibiani”), in the republic of Ghana.   Recent Highlights:Health and safety: Lost Time Incident Frequency Rate of 0.00, and Total Recordable Incident Frequency Rate of 0.00 for year-to-date 2025 Project Cost: Total spent to date of US$32M versus US$32M budgeted (pre-tax) Status: Construction and commissioning are complete12 h/d operation to process Bibiani ore started on September 27, 2025 24 h/d operation expected to start on September 30, 2025 and optimization to achieve +85% gold recovery will progress through October 2025Bibiani...

MONACO, Sept. 29, 2025 (GLOBE NEWSWIRE) — Costamare Bulkers Holdings Limited (“Costamare Bulkers” or the “Company”) (NYSE: CMDB) announced today that it has signed a Strategic Cooperation Agreement (the “Agreement”) with Cargill International S.A. (“Cargill”). Under the Agreement, the Company has agreed to:Transfer to Cargill the majority of its trading book comprising of chartered-in vessels, cargo transportation commitments as well as derivative positions; Charter to Cargill four Supramax vessels for a period of four to six months; Enter into a bunkering services agreement with Seascale Energy (a joint venture between Cargill and Hafnia), covering the owned and operating fleet; Enter into an agreement in respect of decarbonisation and vessel efficiency strategies and implementing decarbonisation projects; Explore opportunities...

-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026- –SP16 has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat CIPN, synergistically complementing Halneuron®, the Company’s late stage NaV1.7 inhibitor, which has demonstrated significant pain reduction in previous Phase 2 studies- -Webcast today, September 29, 2025, at 8:30 a.m. Eastern Time- ATLANTA, Sept. 29, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced that in an all-stock transaction, it has secured a royalty free,...